(Q38100299)

28 August 2017

title

PARP inhibitors: polypharmacology versus selective inhibition (English)

1 reference

28 August 2017

1 reference

3

1 reference

28 August 2017

Torun Ekblad

1

1 reference

28 August 2017

Emidio Camaioni

series ordinal

2

1 reference

28 August 2017

Antonio Macchiarulo

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

24 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

280

1 reference

28 August 2017

issue

15

1 reference

28 August 2017

page(s)

3563-3575

1 reference

New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

New readers and interpretations of poly(ADP-ribosyl)ation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

The DNA damage response and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Toward specific functions of poly(ADP-ribose) polymerase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

PARP-3 and APLF function together to accelerate nonhomologous end-joining

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Tankyrase-targeted therapeutics: expanding opportunities in the PARP family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Tankyrases as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Therapeutic applications of PARP inhibitors: anticancer therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

PARP inhibitors in cancer therapy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

A review of PARP inhibitors: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Targeting the DNA damage response in oncology: past, present and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Neuronal accumulation of poly(ADP-ribose) after brain ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Poly(ADP-ribose) signaling in cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Activation of the poly(ADP-ribose) polymerase pathway in human heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primar

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Role of PARP inhibitors in cancer biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Phase 0 trials: an industry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Destabilization of Zn2+ coordination in ADP-ribose transferase (polymerizing) by 6-nitroso-1,2-benzopyrone coincidental with inactivation of the polymerase but not the DNA binding function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Prevention of tumorigenesis of oncogene-transformed rat fibroblasts with DNA site inhibitors of poly(ADP ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

PARP inhibitors stumble in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Drug profiling: knowing where it hits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Predicting new molecular targets for known drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

21 January 2018

Systems chemical biology

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Relating protein pharmacology by ligand chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Global mapping of pharmacological space

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Probing the links between in vitro potency, ADMET and physicochemical parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Can we rationally design promiscuous drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Fragments, network biology and designing multiple ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Inhibition of matrix metalloproteinase-2 by PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Unusual increase in lumbar network excitability of the rat spinal cord evoked by the PARP-1 inhibitor PJ-34 through inhibition of glutamate uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Discovery of ligands for ADP-ribosyltransferases via docking-based virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Data completeness—the Achilles heel of drug-target networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

(ADP-ribose)n participates in DNA excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12298

21 January 2018

Identifiers

DOI

10.1111/FEBS.12298

1 reference

28 August 2017

1 reference